Figure 2From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies Tumor shrinkage was confirmed (B) after 4 months of treatment with apatinib comparing with baseline (A).Back to article page